

Global Cancer Vaccine Market & Clinical Trials Outlook 2028

https://marketpublishers.com/r/G1CC18B328DEEN.html

Date: July 2022

Pages: 600

Price: US\$ 3,300.00 (Single User License)

ID: G1CC18B328DEEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Cancer Vaccine Market & Clinical Trials Outlook 2028 Highlights:

Global and Regional Market Size Insight 2022 Till 2028

Cancer Vaccine Market Insight & Forecast By 10 Countries 2022 Till 2028

Cancer Vaccine Market Insight & Forecast By 10 Different Cancers 2022 Till 2028

Approved Cancer Vaccines Patent, Price, & Dosage Analysis

Insight On More Than 350 Cancer Vaccines in Clinical Trials

Cancer Vaccines Trials Insight By Company, Country and Indication

Insight On More Than 20 Cancer Vaccines Commercially Available In Market

The use of vaccines for the prevention of infectious disease represents one of the greatest achievements in modern medicine. Owing to their advantages, research studies have also focused to explore the potential of vaccines in the prevention or management of chronic diseases including cancer. Cancer vaccine represents unique approach to cancer therapy which alters the interaction of the host and the tumor, enlisting the patient's tumor response to attack cancer cells. Further, the immunologic



memory associated with the administration of vaccines also gained the interest of researchers to invest in this segment.

Till date, both therapeutic as well as preventive cancer vaccines have gained entry into the global market. Several cancer vaccines including Gardasil, Gardasil 9, Cecolin, or Cervarix have been approved to prevent HPV infection which target high risk HPV strains responsible for nearly all cervical cancers and are also linked to some throat, anal, and other cancers. In contrast, Provenge was the first therapeutic vaccine globally approved in 2010 for the management of prostate cancer. Apart from this, CemaVax, Riavax, and Vaxira have also been approved for the management of non-small cell lung cancer and pancreatic cancer. The entrance of vaccines has shown to greatly transform the paradigm of cancer treatment.

Currently, the pipeline of cancer vaccine is highly crowded which are increasingly reporting encouraging success in clinical trials across wide range of cancers. Several vaccines are also awaiting marketing approval or commercialization. For instance, US FDA is currently reviewing BLA application for N-803 plus Bacillus Calmette-Gu?rin as treatment for patients with BCG-unresponsive non-muscle invasive bladder cancer. Apart from this, Cervac has been approved in India and is expected to be available in the market soon. The presence of wide range of clinical pipeline products indicates strong future presence of the market.

With the continuous research and development activities in this domain, scientists have also developed other enhanced platforms for vaccine development including mRNA vaccines, personalized neoantigen cancer vaccines, stem cells, and others. Although these are present in early stages of clinical development, these represent huge potential across wide range of cancers. Further, the market will also experience growth with the introduction of artificial intelligence algorithms which aid in the precise detection of neoantigens and also factor the early development of companies. Several top players in the market has utilized machine learning to develop their proprietary artificial intelligence algorithm for the characterization of neoantigens and ultimately developing personalized neoantigen cancer vaccines.

In last few years, pharmaceutical companies have also entered into collaboration with artificial intelligence players to develop potential cancer vaccines. For instance in 2022, CureVac entered into research and option agreement with myNEO which will aim to identify specific antigens found on the surface of tumors for the development of vaccines. To achieve this goal, myNEO will leverage its biological datasets and its integrated machine learning and bioinformatics platform to identify and validate specific



antigen targets predicted to elicit strong immune response. Apart from this, myNEO also collaborated with Abera Bioscience to develop personalized cancer vaccines. Other key players in the global market are Argos Therapeutics, Nykode Therapeutics, Merck, Regeneron, GlaxoSmithKline, CureVac, Dendreon, Sanofi, and OSE Immunotherapeutics.

As per our report findings, the global cancer vaccine market is expected to surpass US\$ 15 Billion by 2028. The significant increase in the growth of market is mainly attributed to encouraging sales of HPV cancer vaccines and rising awareness among individuals regarding the benefits of HPV vaccination. Apart from this, several investigational cancer vaccines have progressed towards late stage clinical trials and are expected to gain market authorization, which will also have a positive impact on the growth of market.



Contents

1. INTRODUCTION TO CANCER VACCINES

2. MECHANISM OF CANCER VACCINES

- 2.1 Idiotype Cancer Vaccine Mechanism
- 2.2 Cellular Cancer Vaccines Mechanism
- 2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
- 2.4 Peptide Cancer Vaccine Mechanism
- 2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. GLOBAL CANCER VACCINE MARKET OVERVIEW

- 3.1 Current Market Scenario
- 3.2 Future Market Opportunity

4. CANCER VACCINE MARKET INSIGHT BY REGION

- 4.1 US
- 4.2 Europe
- 4.3 China
- 4.4 Japan
- 4.5 India
- 4.6 South Korea
- 4.7 Australia
- 4.8 Cuba
- 4.9 Canada
- 4.10 UK

5. CANCER VACCINE MARKET INSIGHT BY INDICATION

- 5.1 Human papillomavirus Associated Cancer
- 5.2 Lung Cancer
- 5.3 Pancreatic Cancer
- 5.4 Prostate Cancer
- 5.5 Bladder Cancer
- 5.6 Melanoma
- 5.7 Breast Cancer



- 5.8 Colorectal Cancer
- 5.9 Glioblastoma
- 5.10 Ovarian Cancer

6. APPROVED CANCER VACCINES - PRICE, & DOSAGE ANALYSIS

This Chapter Give Insight On 11 Cancer Vaccine Commercially Available In Market

7. GLOBAL CANCER VACCINES CLINICAL PIPELINE OVERVIEW

- 7.1 By Company
- 7.2 By Country
- 7.3 By Patient Segment/Disease Stage
- 7.4 By Phase

8. GLOBAL CANCER VACCINES CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE

- 8.1 Research
- 8.2 Preclinical
- 8.3 Clinical
- 8.4 Phase-I
- 8.5 Phase-I/II
- 8.6 Phase-II
- 8.7 Phase-III/II
- 8.8 Phase-III
- 8.9 Preregistration
- 8.10 Registered

9. MARKETED CANCER VACCINES CLINICAL INSIGHT BY COMPANY & INDICATION

10. COMPETITIVE LANDSCAPE

- 10.1 Anixa Bioscience
- 10.2 Argos Therapeutics
- 10.3 AstraZeneca
- 10.4 BioNTech
- 10.5 Bristol Myers Squibb



- 10.6 Champions Oncology
- 10.7 CureVac
- 10.8 Elicio Therapeutics
- 10.9 ETheRNA
- 10.10 GlaxoSmithKline
- 10.11 ImmunityBio
- 10.12 Imugene
- 10.13 In3Bio
- 10.14 Merck
- 10.15 Mayo Clinic
- 10.16 Nykode Therapeutics
- 10.17 Regeneron
- 10.18 Roche
- 10.19 TVAX Biomedical
- 10.20 UbiVac
- 10.21 Ultimovacs
- 10.22 VBI vaccines



List Of Figures

LIST OF FIGURES

Figure 1-1: Categorization & Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines
Figure 3-1: Global – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
Figure 3-2: Cancer Vaccine - Market Size by Region (US\$ Million), 2021
Figure 3-3: Cancer Vaccine - Market Size by Region (%), 2021
Figure 3-4: Global – Cancer Vaccine Market Size (US\$ Billion), 2022 - 2028
Figure 4-1: US - Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
Figure 4-2: US vs. ROW – Cancer Vaccine Market Size (US\$ Million), 2021
Figure 4-3: US vs. ROW – Cancer Vaccine Market Size (%), 2021
Figure 4-4: US - Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
Figure 4-5: Europe – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
Figure 4-6: Europe vs. ROW – Cancer Vaccine Market Size (US\$ Million), 2021
Figure 4-7: Europe vs. ROW – Cancer Vaccine Market Size (%), 2021
Figure 4-8: Europe – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
Figure 4-9: China – Market Share of HPV Vaccine Suppliers (%), 2020
Figure 4-10: China – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
Figure 4-11: China – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
Figure 4-12: Japan – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
Figure 4-13: Japan – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
Figure 4-14: India – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
Figure 4-15: India – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
Figure 4-16: South Korea – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
Figure 4-17: South Korea – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
Figure 4-18: Australia – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
Figure 4-19: Australia – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
Figure 4-20: Cuba – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
Figure 4-21: Cuba – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
Figure 4-22: Canada – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
Figure 4-23: Canada – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
Figure 4-24: UK - Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
Figure 4-25: UK - Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
Figure 5-1: Global – HPV Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
Figure 5-2: Global – HPV Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
Figure 5-3: Global – Lung Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
Figure 5-4: Global – Lung Cancer Vaccine Market Size (US\$ Million), 2022 - 2028



- Figure 5-5: Global Pancreatic Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 5-6: Global Pancreatic Cancer Vaccine Market Size (US\$ Million), 2022 2028
- Figure 5-7: Global Prostate Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 5-8: Global Prostate Cancer Vaccine Market Size (US\$ Million), 2022 2028
- Figure 5-9: Global Bladder Cancer Vaccine Market Size (US\$ Million), 2022 2028
- Figure 5-10: Global Melanoma Vaccine Market Size (US\$ Million), 2025 2028
- Figure 5-11: Global Breast Cancer Vaccine Market Size (US\$ Million), 2024 2028
- Figure 5-12: Global Colorectal Cancer Vaccine Market Size (US\$ Million), 2025 2028
- Figure 5-13: Global Glioblastoma Vaccine Market Size (US\$ Million), 2025 2028
- Figure 5-14: Global Ovarian Cancer Vaccine Market Size (US\$ Million), 2025 2028
- Figure 6-1: Gardasil Approval Year by Region
- Figure 6-2: Gardasil 9 Approval Year by Region
- Figure 6-3: US Gardasil Approval Year by Indication
- Figure 6-4: Canada Gardasil Approval Year by Indication
- Figure 6-5: Gardasil 9 Patent Expiration Year by Region
- Figure 6-6: US Cost of 5ml & Per Unit Cost of Gardasil 9 Intramuscular Suspension (US\$), July'2022
- Figure 6-7: UK Per Unit Cost of Gardasil & Gardasil 9 Injection (GBP/US\$), July'2022
- Figure 6-8: South Korea Per Unit Cost of Gardasil Injection (KRW/US\$), July'2022
- Figure 6-9: Global Gardasil/ Gardasil 9 Sales Value (US\$ Million), Q1'2021 & Q1'2022
- Figure 6-10: Global Gardasil/ Gardasil 9 Sales Value (US\$ Million), 2018 2021
- Figure 6-11: Global Gardasil/ Gardasil 9 Quarterly Sales Value (US\$ Million), 2021
- Figure 6-12: Global Gardasil/ Gardasil 9 Quarterly Sales Value (US\$ Million), 2020
- Figure 6-13: Cervarix Approval Year by Region
- Figure 6-14: UK Per Unit Cost of Cervarix Injection (GBP/US\$), July'2022
- Figure 6-15: UK Cost of Single Cycle & Total Cost of Treatment with Cervarix (GBP/US\$), July'2022
- Figure 6-16: South Korea Per Unit Cost of Cervarix Injection (KRW/US\$), July'2022
- Figure 6-17: Cervarix Sales Value by Region (Euro/US\$ Million), Q1'2022
- Figure 6-18: Cervarix Sales Value by Region (%), Q1'2022
- Figure 6-19: Global Cervarix Sales Value (Euro/US\$ Million), 2019 2021
- Figure 6-20: Europe Cervarix Sales Value (Euro/US\$ Million), 2019 2021
- Figure 6-21: Cervarix Sales Value by Region (Euro/US\$ Million), 2021
- Figure 6-22: Cervarix Sales Value by Region (%), 2021
- Figure 6-23: US Cost of 250ml & Per Unit Cost of Proenge Intraveneous Suspension (US\$), July'2022
- Figure 6-24: India Per Unit Cost of Mycidac-C Injection (INR/US\$), July'2022



Figure 7-1: Global - Number of Cancer Vaccines in Clinical Trials by Company, 2022 till 2028

Figure 7-2: Global - Number of Cancer Vaccines in Clinical Trials by Country, 2022 till 2028

Figure 7-3: Global - Number of Cancer Vaccines Clinical Trials by Disease Stage, 2022 till 2028

Figure 7-4: Global - Number of Cancer Vaccine in Clinical Trials by Phase, 2022 till 2028



I would like to order

Product name: Global Cancer Vaccine Market & Clinical Trials Outlook 2028

Product link: https://marketpublishers.com/r/G1CC18B328DEEN.html

Price: US\$ 3,300.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G1CC18B328DEEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970